MedPath

Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement

Early Phase 1
Completed
Conditions
Stroke
Problem of Aging
Registration Number
NCT01376011
Lead Sponsor
Brigham and Women's Hospital
Brief Summary

The purpose of this study is to find out if quercetin can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
106
Inclusion Criteria
  • healthy volunteers between the ages of 18-75 years old
Exclusion Criteria
  • subjects taking vasoactive medications
  • hypertension or vascular disease
  • asthma
  • smokers
  • pregnant women
  • cancer
  • diabetes mellitus
  • history of seizures
  • history of stroke or head trauma
  • subjects taking digoxin, cyclosporine,felodipine, estradiol, or quinolone antibiotics
  • poor transcranial Doppler insonation windows

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Define change from baseline levels of HIF-1 concentration and 3 of its regulated proteins after 6 months of quercetin (versus placebo) dietary intake.6 months

Baseline and 6 month blood samples will be analyzed for levels of HIF-1, VEGF, EPO, and NOS

Determine change from baseline brain blood flow after 6 months of quercetin (versus placebo) dietary intake.6 months

Determine cerebral vasomotor reactivity response to 6 months of quercetin intake by measuring changes in middle cerebral artery (MCA) blood flow velocity in response to changes in end-tidal CO2, and assess neurovascular coupling by measuring changes in MCA flow velocity in response to neuropsychological tasks.

Secondary Outcome Measures
NameTimeMethod
Define change from baseline performance in a battery of cognitive tasks after 6 months of quercetin (versus placebo) dietary intake.6 months

Assess effects of 6 months of quercetin intake on cognitive function using a cognitive battery designed to asses both memory and executive function.

Trial Locations

Locations (1)

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.